First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study † † Presented in part at the 15th World Congress on Lung Cancer, Sydney, Australia 2013.
Titel:
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study † † Presented in part at the 15th World Congress on Lung Cancer, Sydney, Australia 2013.
Auteur:
Wu, Y.-L. Zhou, C. Liam, C.-K. Wu, G. Liu, X. Zhong, Z. Lu, S. Cheng, Y. Han, B. Chen, L. Huang, C. Qin, S. Zhu, Y. Pan, H. Liang, H. Li, E. Jiang, G. How, S.H. Fernando, M.C.L. Zhang, Y. Xia, F. Zuo, Y.